Shopping Cart
Remove All
Your shopping cart is currently empty
Briakinumab (Synonyms: J 695, BSF415977, BSF 415977, ABT-874, ABT874, A-796874.0)
Catalog No. T76935 Copy Product Info
🥰Excellent
Briakinumab (ABT-874) is a monoclonal antibody targeting IL-12, used in the study of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.
Briakinumab
Copy Product Info🥰Excellent
Catalog No. T76935
Synonyms J 695, BSF415977, BSF 415977, ABT-874, ABT874, A-796874.0
Briakinumab (ABT-874) is a monoclonal antibody targeting IL-12, used in the study of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.
Briakinumab
Cas No. 339308-60-0
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | In Stock | In Stock | |
| 5 mg | $562 | In Stock | In Stock | |
| 10 mg | $845 | - | In Stock | |
| 25 mg | $1,250 | - | In Stock | |
| 50 mg | $1,680 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.53% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Briakinumab (ABT-874) is a monoclonal antibody targeting IL-12, used in the study of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. |
| Targets&IC50 | FcRn:0.27 μM (Kd) |
| In vitro | The affinity of Briakinumab to FcRn was Kd = 0.27μM. [1] |
| In vivo | Administering Briakinumab to FcRn knockout (KO) mice via a tail vein, the Briakinumab treated group showed faster clearance compared to wild-type mice. [1] |
| Synonyms | J 695, BSF415977, BSF 415977, ABT-874, ABT874, A-796874.0 |
| Reactivity | Human |
| Verified Activity | Immobilized Human IL-12 p35 (N-His) & IL-12 p40 Protein at 2 μg/mL (30 μL/well) can bind Briakinumab. The EC50 is 3.074 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | IL-12 |
| Molecular Weight | 143.86 kDa |
| Cas No. | 339308-60-0 |
| Isotype | Human IgG1 lambda2 |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Briakinumab | purchase Briakinumab | Briakinumab cost | order Briakinumab | Briakinumab in vivo | Briakinumab in vitro | Briakinumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.